These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 16247417)

  • 1. Daclizumab for children with corticosteroid refractory graft-versus-host disease.
    Teachey DT; Bickert B; Bunin N
    Bone Marrow Transplant; 2006 Jan; 37(1):95-9. PubMed ID: 16247417
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Replacement of calcineurin inhibitors with daclizumab in patients with transplantation-associated microangiopathy or renal insufficiency associated with graft-versus-host disease.
    Wolff D; Wilhelm S; Hahn J; Gentilini C; Hilgendorf I; Steiner B; Kahl C; Junghanss C; Hartung G; Casper J; Uharek L; Holler E; Freund M
    Bone Marrow Transplant; 2006 Sep; 38(6):445-51. PubMed ID: 16951692
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term follow-up of patients treated with daclizumab for steroid-refractory acute graft-vs-host disease.
    Perales MA; Ishill N; Lomazow WA; Weinstock DM; Papadopoulos EB; Dastigir H; Chiu M; Boulad F; Castro-Malaspina HR; Heller G; Jakubowski AA; O'Reilly RJ; Small TN; Young JW; Kernan NA
    Bone Marrow Transplant; 2007 Sep; 40(5):481-6. PubMed ID: 17618322
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improved survival and preserved antiviral responses after combination therapy with daclizumab and infliximab in steroid-refractory graft-versus-host disease.
    Rao K; Rao A; Karlsson H; Jagani M; Veys P; Amrolia PJ
    J Pediatr Hematol Oncol; 2009 Jun; 31(6):456-61. PubMed ID: 19648797
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recombinant human soluble tumor necrosis factor receptor fusion protein as treatment for steroid refractory graft-versus-host disease following allogeneic hematopoietic stem cell transplantation.
    Busca A; Locatelli F; Marmont F; Ceretto C; Falda M
    Am J Hematol; 2007 Jan; 82(1):45-52. PubMed ID: 16937391
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Daclizumab therapy for children with corticosteroid-resistant acute graft-vs.-host disease.
    Schechter T; Afzal S; Finkelstein Y; Koren G; Doyle J; Dupuis LL
    Pediatr Transplant; 2009 May; 13(3):332-7. PubMed ID: 18482218
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of steroid-resistant acute graft-versus-host disease with daclizumab and etanercept.
    Wolff D; Roessler V; Steiner B; Wilhelm S; Weirich V; Brenmoehl J; Leithaeuser M; Hofmeister N; Junghanss C; Casper J; Hartung G; Holler E; Freund M
    Bone Marrow Transplant; 2005 May; 35(10):1003-10. PubMed ID: 15806135
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term follow-up of children treated with daclizumab for steroid-refractory gastrointestinal GvHD in a prospective study.
    Hamidieh AA; Hadjibabaie M; Ghehi MT; Jalili M; Hosseini A; Pasha F; Behfar M; Ghavamzadeh A
    Pediatr Transplant; 2012 Sep; 16(6):664-9. PubMed ID: 22738324
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Daclizumab, an efficient treatment for steroid-refractory acute graft-versus-host disease.
    Bordigoni P; Dimicoli S; Clement L; Baumann C; Salmon A; Witz F; Feugier P
    Br J Haematol; 2006 Nov; 135(3):382-5. PubMed ID: 16984386
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Daclizumab as useful treatment in refractory acute GVHD: a paediatric experience.
    Miano M; Cuzzubbo D; Terranova P; Giardino S; Lanino E; Morreale G; Castagnola E; Dini G; Faraci M
    Bone Marrow Transplant; 2009 Mar; 43(5):423-7. PubMed ID: 18850021
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thalidomide after allogeneic haematopoietic stem cell transplantation: activity in chronic but not in acute graft-versus-host disease.
    Kulkarni S; Powles R; Sirohi B; Treleaven J; Saso R; Horton C; Atra A; Ortin M; Rudin C; Goyal S; Sankpal S; Meller S; Pinkerton CR; Mehta J; Singhal S
    Bone Marrow Transplant; 2003 Jul; 32(2):165-70. PubMed ID: 12838281
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-interleukin-2 receptor monoclonal antibody (BT 563) in the treatment of severe acute GVHD refractory to systemic corticosteroid therapy.
    Cuthbert RJ; Phillips GL; Barnett MJ; Nantel SH; Reece DE; Shepherd JD; Klingemann HG
    Bone Marrow Transplant; 1992 Nov; 10(5):451-5. PubMed ID: 1464009
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of infliximab-daclizumab combination for the treatment of acute and chronic graft-versus-host disease of the liver and gut.
    Rodriguez V; Anderson PM; Trotz BA; Arndt CA; Allen JA; Khan SP
    Pediatr Blood Cancer; 2007 Aug; 49(2):212-5. PubMed ID: 16261610
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pulse cyclophosphamide for corticosteroid-refractory graft-versus-host disease.
    Mayer J; Krejcí M; Doubek M; Pospísil Z; Brychtová Y; Tomíska M; Rácil Z
    Bone Marrow Transplant; 2005 Apr; 35(7):699-705. PubMed ID: 15696180
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Crypt loss is a marker of clinical severity of acute gastrointestinal graft-versus-host disease.
    Melson J; Jakate S; Fung H; Arai S; Keshavarzian A
    Am J Hematol; 2007 Oct; 82(10):881-6. PubMed ID: 17570511
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sequential use of three monoclonal antibodies in corticosteroid-resistant acute GVHD: a multicentric pilot study including 15 patients.
    Racadot E; Milpied N; Bordigoni P; Cahn JY; Plouvier E; Lioure B; Lutz P; Wijdenes J; Herve P
    Bone Marrow Transplant; 1995 May; 15(5):669-77. PubMed ID: 7670394
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Infliximab treatment for steroid-refractory acute graft-versus-host disease.
    Patriarca F; Sperotto A; Damiani D; Morreale G; Bonifazi F; Olivieri A; Ciceri F; Milone G; Cesaro S; Bandini G; Dini G; Corradini P; Fanin R
    Haematologica; 2004 Nov; 89(11):1352-9. PubMed ID: 15531458
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Successful treatment of steroid-refractory hepatitic variant of liver graft-vs-host disease with pulse cyclophosphamide.
    Mayer J; Krejci M; Pospisil Z; Doubek M; Janikova A; Zackova D; Racil Z; Smardova L; Navratil M; Kamelander J
    Exp Hematol; 2009 Jun; 37(6):767-73. PubMed ID: 19463776
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extracorporeal photopheresis for acute and chronic graft-versus-host disease: does it work?
    Couriel D; Hosing C; Saliba R; Shpall EJ; Andelini P; Popat U; Donato M; Champlin R
    Biol Blood Marrow Transplant; 2006 Jan; 12(1 Suppl 2):37-40. PubMed ID: 16399600
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term use of oral beclomethasone dipropionate for the treatment of gastrointestinal graft-versus-host disease.
    Iyer RV; Hahn T; Roy HN; Battiwalla M; Cooper M; Anderson B; Paplham P; Brown K; Bambach B; Segal BH; McCarthy PL
    Biol Blood Marrow Transplant; 2005 Aug; 11(8):587-92. PubMed ID: 16041308
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.